GlassScriptPhysician profile
Karishma Habbu
NPI 1003341413
$4,259.51
in general payments reported to CMS, 2019-2025
29 companies · $1,185 in 2025
The $1,185 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $260 · 2022: $434 · 2023: $1,555 · 2024: $825 · 2025: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,466 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,466.30 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $542.82 | 2023-2025 | Streamline, Kahook Dual Blade, Via360 |
| Regeneron Healthcare Solutions, INC. | $379.53 | 2025 | Eylea Hd, Eylea |
| Johnson & Johnson Surgical Vision, INC. | $314.72 | 2021-2025 | Tecnis Iol, Catalys System, Tecnis Simplicity |
| Notal Vision, INC. | $306.35 | 2022 | |
| Abbvie INC. | $304.67 | 2022-2024 | |
| Glaukos Corporation | $268.89 | 2023-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite |
| Bausch & Lomb Americas INC. | $223.01 | 2023-2024 | Xipere, Miebo, Envista Mx60 Iol |
| Alcon Vision LLC | $191.92 | 2023-2025 | Clareon, Rocklatan, Argos |
| Dompe US, INC. | $190.68 | 2023-2024 | Oxervate |
| Mallinckrodt Hospital Products INC. | $161.71 | 2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $144.01 | 2022-2025 | Cequa |
| Rxsight INC | $124.03 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Astellas Pharma US INC | $122.41 | 2023-2025 | Izervay |
| Genentech USA, INC. | $110.80 | 2024-2025 | Vabysmo |
| Ani Pharmaceuticals, INC. | $107.87 | 2025 | Purified Cortrophin Gel, Iluvien |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $97.78 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $92.57 | 2024 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $91.58 | 2023-2024 | Syfovre |
| Harrow Eye, LLC | $78.97 | 2024-2025 | Iheezo, Triesence, Vevye |
| Sight Sciences, INC. | $74.88 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Novartis Pharmaceuticals Corporation | $70.30 | 2022-2023 | |
| Amgen INC. | $61.11 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $58.69 | 2023 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $32.25 | 2023 | Acuvue |
| Thea Pharma INC. | $24.47 | 2023 | Iyuzeh |
| Alimera Sciences, INC. | $24.39 | 2023 | Yutiq |
| Ocular Therapeutix, INC. | $23.19 | 2024 | Dextenza |
| Lensar, INC. | $18.94 | 2024 | Lensar Laser System |
| Rayner Intraocular Lenses Limited | $16.97 | 2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karishma Habbu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.